- Medical news articles blogs and discussions Home » Upcoming News » Paediatrics
-
Sort Paediatrics by:
Newest |
Oldest |
Most Popular |
Least Popular |
PARI Pharma's eFlow electronic nebulizer was included in Gilead's (Nasdaq: GILD) recent New Drug Application (NDA) submittal to the U.S. Food and Drug Administration (FDA) for marketing approval of aztreonam lysine for inhalation (75 mg three times daily). Aztreonam lysine for inhalation, delivere
read more »
Source:http://www.medicalnewstoday.com
Discuss Bury
Source:http://www.medicalnewstoday.com
Discuss Bury
A new US study found that lung transplants did not prolong life for the majority of children studied who had cystic fibrosis (CF) compared with CF children who did not undergo lung transplants. However, critics suggest the conclusions may no longer apply because in the US there is a new system for
read more »
Source:http://www.medicalnewstoday.com
Discuss Bury
Source:http://www.medicalnewstoday.com
Discuss Bury
Lung transplantation, the therapy almost every cystic fibrosis patient (CF) considers at some point to prolong survival, rarely helps children with the disease live longer and, in fact, often increases their risk of dying, University of Utah researchers conclude in the most extensive study of the i
read more »
Source:http://www.medicalnewstoday.com
Discuss Bury
Source:http://www.medicalnewstoday.com
Discuss Bury
Commenting on a study of lung transplantation for children with cystic fibrosis, a leading pediatric pulmonologist calls the study "startling" in an editorial in this week's New England Journal of Medicine that accompanies the study. Julian Allen, M.D. [click link for full article]
read more »
Source:http://www.medicalnewstoday.com
Discuss Bury
Source:http://www.medicalnewstoday.com
Discuss Bury
Aradigm Corporation (OTCBB:ARDM) announced it has initiated a Phase 2 study of its proprietary inhaled liposomal formulation of ciprofloxacin in patients with cystic fibrosis. This safety and efficacy study follows the successful completion of a Phase 1 safety, tolerability and pharmacokinetics tri
read more »
Source:http://www.medicalnewstoday.com
Discuss Bury
Source:http://www.medicalnewstoday.com
Discuss Bury
Gilead Sciences, Inc. (Nasdaq:GILD) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of aztreonam lysine for inhalation (75 mg three times daily), an investigational therapy in development for people with cystic fibrosis
read more »
Source:http://www.medicalnewstoday.com
Discuss Bury
Source:http://www.medicalnewstoday.com
Discuss Bury
Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has adopted a negative opinion on the marketing authorization for natalizumab as a treatment f
read more »
Source:http://www.medicalnewstoday.com
Discuss Bury
Source:http://www.medicalnewstoday.com
Discuss Bury
UCB announced that it has been informed by the European Medicines Agency (EMEA) that the Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion on the market authorisation application (MAA) in the EU for CIMZIA(R) certolizumab pegol) in the treatment of patients with
read more »
Source:http://www.medicalnewstoday.com
Discuss Bury
Source:http://www.medicalnewstoday.com
Discuss Bury
New clinical standards on the treatment of patients with cystic fibrosis (CF) have been released following an exhaustive review of all available literature.The guidelines, a result of a two-year review of original research and systematic review literature from 1983 to 2006, were published in the se
read more »
Source:http://www.medicalnewstoday.com
Discuss Bury
Source:http://www.medicalnewstoday.com
Discuss Bury
Medinews is an online community dedicated for promoting and discussing latest medical news, research articles and blogs. You can also find regular updates on health news for discussion by health professionals.
